723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioning
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1797629799529709568 |
|---|---|
| author | Lawrence G Lum Martin Gutierrez Sunil Patel Michele Donato Jee Hyun Park Tania Felizardo Daniel H Fowler Morgan Finlay Ronit Reich-Slotky Research Nurse Coordinator |
| author_facet | Lawrence G Lum Martin Gutierrez Sunil Patel Michele Donato Jee Hyun Park Tania Felizardo Daniel H Fowler Morgan Finlay Ronit Reich-Slotky Research Nurse Coordinator |
| author_sort | Lawrence G Lum |
| collection | DOAJ |
| first_indexed | 2024-03-11T10:58:08Z |
| format | Article |
| id | doaj.art-5359fdaca25b4fb893d0d06e05bb990e |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-11T10:58:08Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-5359fdaca25b4fb893d0d06e05bb990e2023-11-13T00:25:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.0723723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioningLawrence G Lum0Martin Gutierrez1Sunil Patel2Michele Donato3Jee Hyun Park4Tania Felizardo5Daniel H Fowler6Morgan Finlay7Ronit Reich-Slotky8Research Nurse Coordinator92University of Virginia, Charlottesville, VA, USA5Hackensack University Medical Center, Hackensack, NJ, USA1Hackensack Meridian Health, Edison, NJ, USAStanford Institute for Immunity Transplantation and Infection, Stanford, California, USA1Rapa Therapeutics, Rockville, MD, USA1Rapa Therapeutics, Rockville, MD, USA1Rapa Therapeutics, Rockville, MD, USA1Hackensack Meridian Health, Hackensack, NJ, USA1Hackensack Meridian Health, Edison, NJ, USA1Hackensack Meridian Health, Edison, NJ, USA |
| spellingShingle | Lawrence G Lum Martin Gutierrez Sunil Patel Michele Donato Jee Hyun Park Tania Felizardo Daniel H Fowler Morgan Finlay Ronit Reich-Slotky Research Nurse Coordinator 723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioning Journal for ImmunoTherapy of Cancer |
| title | 723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioning |
| title_full | 723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioning |
| title_fullStr | 723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioning |
| title_full_unstemmed | 723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioning |
| title_short | 723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioning |
| title_sort | 723 metabolically reprogrammed autologous th1 tc1 cell therapy rapa 201 yields promising safety and efficacy in post pd l 1 solid tumor patients without lymphodepleting host conditioning |
| work_keys_str_mv | AT lawrenceglum 723metabolicallyreprogrammedautologousth1tc1celltherapyrapa201yieldspromisingsafetyandefficacyinpostpdl1solidtumorpatientswithoutlymphodepletinghostconditioning AT martingutierrez 723metabolicallyreprogrammedautologousth1tc1celltherapyrapa201yieldspromisingsafetyandefficacyinpostpdl1solidtumorpatientswithoutlymphodepletinghostconditioning AT sunilpatel 723metabolicallyreprogrammedautologousth1tc1celltherapyrapa201yieldspromisingsafetyandefficacyinpostpdl1solidtumorpatientswithoutlymphodepletinghostconditioning AT micheledonato 723metabolicallyreprogrammedautologousth1tc1celltherapyrapa201yieldspromisingsafetyandefficacyinpostpdl1solidtumorpatientswithoutlymphodepletinghostconditioning AT jeehyunpark 723metabolicallyreprogrammedautologousth1tc1celltherapyrapa201yieldspromisingsafetyandefficacyinpostpdl1solidtumorpatientswithoutlymphodepletinghostconditioning AT taniafelizardo 723metabolicallyreprogrammedautologousth1tc1celltherapyrapa201yieldspromisingsafetyandefficacyinpostpdl1solidtumorpatientswithoutlymphodepletinghostconditioning AT danielhfowler 723metabolicallyreprogrammedautologousth1tc1celltherapyrapa201yieldspromisingsafetyandefficacyinpostpdl1solidtumorpatientswithoutlymphodepletinghostconditioning AT morganfinlay 723metabolicallyreprogrammedautologousth1tc1celltherapyrapa201yieldspromisingsafetyandefficacyinpostpdl1solidtumorpatientswithoutlymphodepletinghostconditioning AT ronitreichslotky 723metabolicallyreprogrammedautologousth1tc1celltherapyrapa201yieldspromisingsafetyandefficacyinpostpdl1solidtumorpatientswithoutlymphodepletinghostconditioning AT researchnursecoordinator 723metabolicallyreprogrammedautologousth1tc1celltherapyrapa201yieldspromisingsafetyandefficacyinpostpdl1solidtumorpatientswithoutlymphodepletinghostconditioning |